Integra LifeSciences (NASDAQ:IART) Releases Q1 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its first quarter earnings guidance on Tuesday. The company provided EPS guidance of $0.40 to $0.45 for the period, compared to the consensus EPS estimate of $0.54. The company issued revenue guidance of $375 million to $385 million, compared to the consensus revenue estimate of $400.11 million. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Integra LifeSciences Trading Up 14.1 %

NASDAQ:IART traded up $3.12 on Tuesday, reaching $25.17. 473,108 shares of the stock traded hands, compared to its average volume of 558,733. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences has a 1-year low of $16.81 and a 1-year high of $44.91. The company’s 50 day moving average is $23.68 and its 200-day moving average is $21.81. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -277.74, a price-to-earnings-growth ratio of 0.73 and a beta of 1.17.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.86 by $0.11. The company had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. Integra LifeSciences’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.89 earnings per share. Equities research analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on IART. Morgan Stanley started coverage on Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 target price on the stock. Citigroup boosted their price target on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $23.00.

Insider Buying and Selling

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at $1,357,357.12. This represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.10% of the stock is owned by company insiders.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.